Replimune Group, Inc. financial data

Symbol
REPL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
500 Unicorn Park, Woburn, MA
State of incorporation
Delaware
Fiscal year end
March 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.23K % -33.5%
Debt-to-equity 25.5 % +65.1%
Return On Equity -52.2 % -47.1%
Return On Assets -41.6 % -35.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 68.3M shares +15.8%
Common Stock, Shares, Outstanding 68.3M shares +15.8%
Entity Public Float 606M USD +24.4%
Common Stock, Value, Issued 68K USD +19.3%
Weighted Average Number of Shares Outstanding, Basic 69.2M shares +4.25%
Weighted Average Number of Shares Outstanding, Diluted 69.2M shares +4.25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 177M USD +29.1%
General and Administrative Expense 59M USD +8.51%
Operating Income (Loss) -236M USD -23.3%
Nonoperating Income (Expense) 16.7M USD +55.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -220M USD -21.4%
Income Tax Expense (Benefit) 207K USD -57.7%
Net Income (Loss) Attributable to Parent -220M USD -21.2%
Earnings Per Share, Basic -3.27 USD/shares -10.5%
Earnings Per Share, Diluted -3.27 USD/shares -10.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 152M USD +42.4%
Assets, Current 480M USD -12.7%
Property, Plant and Equipment, Net 11.4M USD +49.7%
Operating Lease, Right-of-Use Asset 4.48M USD -12.9%
Assets 535M USD -11.4%
Accounts Payable, Current 864K USD -82.3%
Liabilities, Current 35.7M USD +10.7%
Operating Lease, Liability, Noncurrent 3.6M USD -16.2%
Other Liabilities, Noncurrent 786K USD +36%
Liabilities 109M USD +20.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.32M USD +9.03%
Retained Earnings (Accumulated Deficit) -755M USD -41.1%
Stockholders' Equity Attributable to Parent 426M USD -17%
Liabilities and Equity 535M USD -11.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -49.2M USD -1.19%
Net Cash Provided by (Used in) Financing Activities 96.6M USD +8645%
Net Cash Provided by (Used in) Investing Activities 29.8M USD +304%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 68.3M shares +15.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 77.2M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 153M USD +41.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.05M USD +61.1%
Deferred Tax Assets, Valuation Allowance 162M USD +42.1%
Deferred Tax Assets, Gross 173M USD +37.9%
Operating Lease, Liability 4.76M USD -12.3%
Depreciation 700K USD +16.7%
Payments to Acquire Property, Plant, and Equipment 449K USD -58%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -220M USD -23.3%
Lessee, Operating Lease, Liability, to be Paid 6.2M USD -16%
Property, Plant and Equipment, Gross 22M USD +42.2%
Operating Lease, Liability, Current 1.16M USD +2.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.14M USD -3.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.17M USD +0.09%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.43M USD -26.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.09M USD -5.07%
Deferred Tax Assets, Operating Loss Carryforwards 142M USD +51.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 8.67M USD -1.03%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.01M USD -8.05%
Operating Lease, Payments 152K USD -42.2%
Additional Paid in Capital 1.18B USD +12.6%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 736K USD +18.5%
Share-based Payment Arrangement, Expense 9.48M USD +7.11%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%